Age-related blood clots are associated with cellular senescence
Researchers at the Buck Institute published their findings in Cell Reports, September 24, identifying 44 specific senescence-associated proteins involved in blood clotting. As more cells accumulate with time, they release a mixture of inflammatory protein that leads to chronic inflammation. Publishing in the September 24 edition of Cell Reports, researchers at the Buck Institute identified 44 specific senescence-associated proteins that are involved in blood clotting, marking the first time that cellular senescence has been associated with age-related blood clots.
The incidence of deep vein thrombosis (DVT) and pulmonary embolism, including venous-thrombosis is very low up until 45 years old, at which point it starts to increase rapidly. It becomes a major cause of death over time. \”By 80, five to six individuals per 1,000 are affected by this condition,\” said Judith Campisi PhD, Buck Professor and senior coauthor of the study. Blood clots can also be a serious side-effect of chemotherapy. This causes a cascade senescence among those receiving treatment. Blood thinners are frequently included in treatment plans, despite their risks.
Scientists from the Campisi Lab and other laboratories around the world work to develop senolytics. These drugs would remove senescent cell debris, which could provide treatment options for a variety of age-related illnesses that are caused by or linked to senescence. These include Alzheimer’s disease and Parkinson’s disease, cardiovascular diseases, osteoarthritis (arthritis), macular degeneration and age-related cancers.
Source:
https://www.buckinstitute.org/news/cellular-senescence-is-associated-with-age-related-blood-clots/
